Related Experiment Video

Updated: May 19, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Unresolving Pneumonia in Type 2 Diabetes: Case Report of Polymicrobial Lung Disease

Micheal Collins Segawa1

  • 1College of Health Sciences Makerere University Kampala Uganda.

Clinical Case Reports
|May 18, 2026
PubMed

Insights

Type 2 diabetes (T2DM) patients with pneumonia require prompt diagnosis and tailored treatment. This case highlights polymicrobial infections, including drug-resistant bacteria and fungi, necessitating early imaging and pleural fluid analysis for effective management.

Area of Science:

  • Infectious Diseases
  • Endocrinology
  • Pulmonology

Background:

  • Polymicrobial pneumonia is a growing concern in patients with type 2 diabetes mellitus (T2DM) due to their immunocompromised state.
  • T2DM predisposes individuals to typical and opportunistic infections, including multidrug-resistant organisms (MDROs) and fungi.
  • Effective management hinges on prompt diagnosis and organism-specific treatment.

Purpose of the Study:

  • To report a case of polymicrobial pneumonia in a patient with newly diagnosed T2DM.
  • To highlight the diagnostic challenges and successful treatment strategies for complex infections in diabetic patients.
  • To emphasize the importance of early diagnostic interventions and multidisciplinary care.

Main Methods:

  • A case report of a 53-year-old male with T2DM presenting with prolonged pneumonia symptoms.
  • Diagnostic imaging revealed a large loculated pleural effusion.
  • Pleural fluid analysis identified multidrug-resistant Klebsiella pneumoniae, Enterobacter spp., and azole-resistant Candida glabrata.

Main Results:

  • Initial empirical antibiotic therapy failed to resolve the infection.
  • Pleural fluid analysis identified a polymicrobial etiology with significant antimicrobial resistance.
  • Successful treatment involved intravenous meropenem, echinocandin, and oral fluconazole, alongside optimized insulin therapy for glycemic control.

Conclusions:

  • Polymicrobial infections, including MDROs and resistant fungi, should be considered in diabetic patients with unresolving pneumonia.
  • Early utilization of imaging and pleural fluid analysis is crucial for identifying causative pathogens.
  • Tailored antimicrobial therapy and multidisciplinary management are essential for improving outcomes in these complex cases.
Keywords:
Candida glabrataKlebsiella pneumoniaemultidrug‐resistant infectionpolymicrobial lung infectiontype 2 diabetes mellitusunresolving pneumonia

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: